CL2014003632A1 - Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients. - Google Patents

Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients.

Info

Publication number
CL2014003632A1
CL2014003632A1 CL2014003632A CL2014003632A CL2014003632A1 CL 2014003632 A1 CL2014003632 A1 CL 2014003632A1 CL 2014003632 A CL2014003632 A CL 2014003632A CL 2014003632 A CL2014003632 A CL 2014003632A CL 2014003632 A1 CL2014003632 A1 CL 2014003632A1
Authority
CL
Chile
Prior art keywords
peritoneal
pleural
washes
systemic
origin
Prior art date
Application number
CL2014003632A
Other languages
Spanish (es)
Inventor
Gareth Ivor Owen
Castillo María Loreto Bravo
Cardemil Sumie Rode Kato
Fredes Mauricio Arturo Cuello
Walden Renán Felipe Orellana
Hevia Pamela Andrea González
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Priority to CL2014003632A priority Critical patent/CL2014003632A1/en
Publication of CL2014003632A1 publication Critical patent/CL2014003632A1/en
Priority to PCT/IB2015/059019 priority patent/WO2016108099A2/en
Priority to ARP150104319A priority patent/AR103303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL2014003632A 2014-12-31 2014-12-31 Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients. CL2014003632A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CL2014003632A CL2014003632A1 (en) 2014-12-31 2014-12-31 Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients.
PCT/IB2015/059019 WO2016108099A2 (en) 2014-12-31 2015-11-20 Method for determining the best treatment for cancer patients, comprising the culture and expansion of cells present in ascites fluid of peritoneal, pleural, peritoneal lavage or systemic lavage origin
ARP150104319A AR103303A1 (en) 2014-12-31 2015-12-28 METHOD THAT INCLUDES THE CULTURE AND EXPANSION OF CELLS PRESENT IN THE ASCYTIC LIQUID OF PERITONEAL ORIGINAL PLEURAL, WASHING PERITONEAL OR SYSTEM WASHING THAT ALLOWS TO DETERMINE THE BEST TREATMENT FOR PATIENTS WITH CANCER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2014003632A CL2014003632A1 (en) 2014-12-31 2014-12-31 Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients.

Publications (1)

Publication Number Publication Date
CL2014003632A1 true CL2014003632A1 (en) 2015-06-26

Family

ID=56613937

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003632A CL2014003632A1 (en) 2014-12-31 2014-12-31 Method comprising the culture and expansion of cells present in ascitic fluid of peritoneal, pleural origin, peritoneal lavage or systemic washes that allows to determine the best treatment for cancer patients.

Country Status (3)

Country Link
AR (1) AR103303A1 (en)
CL (1) CL2014003632A1 (en)
WO (1) WO2016108099A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980703088A (en) * 1995-03-16 1998-09-05 라카일레 지, 필리페 An inkjet recording paper comprising a new precipitated calcium carbonate pigment
EP2207892A4 (en) * 2007-10-15 2010-12-08 Precision Therapeutics Inc METHODS OF SELECTING ACTIVE AGENTS FOR THE TREATMENT OF CANCER
US20140087362A1 (en) * 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US9580678B2 (en) * 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device

Also Published As

Publication number Publication date
AR103303A1 (en) 2017-05-03
WO2016108099A2 (en) 2016-07-07
WO2016108099A3 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
IL282352B (en) Methods for the production of autologous t cells used in the treatment of b-cell malignancies and other types of cancer and preparations thereof
IL283733A (en) Methods for treating cancer using activated t cells
IL271242B (en) Systems and methods for agreeing to transactional content
IL259162B (en) fgfr2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
IL254294A0 (en) Topical local neuro-effective treatment with cannabinoids
HUE057817T2 (en) Anti-LAG-3 antibodies for the treatment of hematological malignancies
SI3331915T1 (en) Checkpoint inhibitors for use in the treatment of blood-borne cancers
SI3142751T1 (en) Anti-B7-H1 and anti-CTLA-4 antibodies for the treatment of non-small cell lung cancer
PL3198033T3 (en) APPLICATION OF FGFR MUTATED GENE PANELS IN IDENTIFICATION OF PATIENTS WITH CANCER WHO WILL RESPOND TO FGFR INHIBITOR TREATMENT
IL252361A0 (en) Preparations and methods for the treatment and diagnosis of cancers resistant to chemotherapy
MX2016002137A (en) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.
DK3693158T3 (en) ASYMMETRIC PROCESSING PROCEDURE FOR REDUCTION OF CURVE IN LAMINATE STRUCTURES
PL3140097T3 (en) THE MULTILAYER BODY AND THE METHOD OF ITS PRODUCTION
ME03558B (en) ANTI-LAG-3 ANTIBODIES MOLECULES AND THEIR USES
DK3067404T3 (en) PROCEDURES FOR USE IN OIL AND / OR GAS SOURCES
SI3218005T1 (en) COMPOUNDS ACTING WITH GLYCAN AND METHODS OF USE
PL3186244T3 (en) URIDINE DIOXOLATE ANALOGS IN THE TREATMENT OF CANCER
MX372823B (en) BORONIC ACID DERIVATIVES.
DK3356575T3 (en) High pressure or differential pressure electrolysis cell
MX2016011022A (en) METHOD FOR THE TREATMENT OF UNDERGROUND DEPOSITS.
BR112017008799A2 (en) apilimod compositions and methods of use in treating kidney cancer
DK3779120T3 (en) CHEMICAL SOURCE SOURCES FOR USE IN BOREHOLE OPERATIONS
PL3236960T3 (en) Fluralaner for use in the treatment of demodicosis
PL3174510T3 (en) METHOD AND PRODUCT FOR KEEPING THE MENSTRUATION FLUID INSIDE THE Vagina
PL3978074T3 (en) TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1